Nektar Therapeutics Financial Results Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 4 Calls Today's Calls

Call Details Nektar Therapeutics Financial Results Conference Call (Q3 2009) Wed, Nov 4, 2009, 5:00 pm Eastern Listen to the archived event audio About Nektar Therapeutics (NasdaqGS:NKTR) Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies. Its technology platforms comprise PEGylation Technology designed to enhance the performance of various drug classes, including macromolecules, small molecules, and other drugs. The company’s technologies are used in 10 approved products; 3 partner programs that have been filed for with the FDA; and 12 development programs in human clinical trials. Its partnered products include NKTR-061, a Phase II clinical product for gram-negative pneumonias; and Ciprofloxacin Inhalation Powder, a Phase II clinical product for lung infections. The company’s partnered product portfolio also comprises Neulasta for neutropenia; PEGASYS for Hepatitis-C; Somavert for Acromegaly; PEG-INTRON for Hepatitis-C; Macugen for age-related macular degeneration; CIMZIA for Crohn's disease; MIRCERA for renal anemia and chronic kidney disease; CIMZIA for rheumatoid arthritis; Hematide, a Phase III product for Anemia; MAP0004, a Phase III product for Migraine; Macugen, a Phase II clinical trial product for diabetic macular edema and retinal vein occlusion; and CDP 791, a Phase II product for nonsmall cell lung cancer. In addition, Nektar’s proprietary products include NKTR-105 (PEGylated docetaxel) for colorectal and non-small-cell lung cancer; NKTR-102, a Phase II trial product for colorectal cancer, metastatic breast, metastatic cervical cancer, and platinum resistant ovarian cancer; NKTR-118, a Phase II product for opioid-induced constipation and other manifestations of opioid bowel dysfunction; and NKTR-063 (inhaled vancomycin), a proprietary antibiotic being developed for Gram-positive pneumonia, including MRSA infections, which is in Phase I clinical trials in the U.K. and scheduled to enter Phase II trials in the U.S. in the first half of 2009. The company was founded in 1990 and is headquartered in San Carlos, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings